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1. INTRODUCTION
Anticoagulants are used as preventive agents in deep vein 
thrombosis to prevent blood clots and as prophylactic in 
patients having mechanical heart valves for lifelong therapy 
(1). The coagulation cascade is a complex system linking 
various biomolecular proteins which are known as clotting 
factors. In recent years these clotting factors are emerged 
as potential targets for the anticoagulant molecules (2). 
Current anticoagulant therapy has various side effects like 
enhanced chance of bleeding, variable patient responses, 
heparin-induced thrombocytopenia (HIT) and the inability 
to inhibit clot-bound thrombin are associated with current 
anticoagulant (3-5). To overcome these limitations, newer 
direct inhibitors of thrombin and factor Xa are considered 
to be a better option to indirect clotting factor inhibitors. 
An important advantage of direct inhibition is that both 
circulating and clot-bound thrombin can be inhibited 
(6). FXa is an important target due to involvement at the 
downstream in the coagulation cascade, as FXa is present 
at the junction of both extrinsic and intrinsic pathways. 
Traditionally, prophylactic treatment has been based on 
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vitamin K antagonists (VKAs), Warfarin, a coumarin 
derivative has been the drug of choice for the prevention and 
treatment of arterial and venous thrombotic disorders for 
more than 60 years (7, 8). As it has narrow therapeutic window 
and various side effects dose monitoring is required for 
warfarin. New oral direct FXa inhibitors like rivaroxaban and 
apixaban anticoagulants are better alternatives for warfarin. 
Rivaroxaban and apixaban are approved for treatment of 
venous thromboembolism (VTE) also stroke prevention 
and systemic embolization in non-valvular atrial fibrillation 
(AF) (9, 10). The occurrence of patients with AF is growing 
significantly worldwide, and around 1%–2% of the world 
population is affected with AF (11-14). QSAR methods have 
a great significance in modern medicinal chemistry due to 
ability to directly correlate molecular structure with biological 
activity of molecules (15, 16). Group based QSAR (GQSAR) 
is a new approach to scrutinize structure activity relationship 
based on molecular fragments of congeneric as well as non-
congeneric set of molecules (17-20). As the name indicates 
GQSAR allows developing quantitative relationship between 
biological activity and various physicochemical descriptors 
calculated for molecular fragments. Thus the fragmentation 
of the molecules forms an essential step in order to carry out 
GQSAR. In this study, we report GQSAR method of QSAR 
to identify important molecular sites and their properties to 
aid in the development of novel FXa inhibitors. The dataset 
of chromen-2-one derivatives developed by Bhatia et al. 
were utilized to develop fragment based GQSAR models. 
The developed GQSAR models were found to be useful for 
framework bounding and optimization of lead molecules as 
potent inhibitors. In addition to that, the developed GQSAR 
models also give idea about essential fragment based features 
this will helpful to medicinal chemist to design combinatorial 
library (19-21).
2. Materials and methods
2.1. Dataset preparation
Dataset of 48 molecules was taken from literature reported by 
Bhatia et al. (1) Structure and activity (pIC50) as mentioned 
in the literature are listed in Table no.1. Structures of pyridyl 
chromen-2-one derivatives were drawn using 2D draw 
module of Vlife MDS 4.4. The 2D structures were converted 
to 3D structures and their energy was minimized on Vlife 
engine platform in batch. Energy minimization was carried 
out using Merck molecular force field (MMFF) and Gasteiger 
charges with 0.01 as convergence criteria (RMS gradient) 
and analytical gradient type was used (20, 22). Template 
file was created by replacing atoms at attachment points on 
a molecule by dummy atom (X). The study was performed 
on Vlife MDS 4.4 supplied by Vlife Sciences, Pvt. Ltd. Pune, 
India.
2.2. Calculation of descriptors:
All the optimized molecules were open in Vlife workspace 
and activity of molecules was imported via insert data 
command from GQSAR module. Total of 535 2D 
descriptors were calculated using VLife MDS 4.4 software. 
Various descriptors like physicochemical, structural, polar 
surface area, Kappa, individual, chi, chiv, chain path count, 
cluster, element count, topological, Baumann alignment 
independent topological descriptors for each molecule 
under study (23). The template used for the fragmentation 
of set of molecules shown in (Fig. 1). List of descriptors 
which were utilized in the present study are described with 
their description in following Table no 1.
Figure 1. Template used for Fragmentation pattern
2.3. Data selection and building GQSAR model
In the present study dataset of 48 molecules were divided into 
test and training sets such that 70% of molecules in training 
set for model building and 30% of molecules in test set for 
validation of model and there will be uniform distribution of 
molecules with respect to the bioactivity of molecules shown 
in Table no. 2. This selection was done by random selection 
of molecules from dataset. 33 molecules were selected for 
training set whereas 15 molecules were selected for test 
set. Multiple linear regression (MLR) method was used 
together with stepwise (SW) forward-backward variable 
selection search algorithm was employed for development 
of the GQSAR model. The GQSAR model with correlation 
coefficient more than 0.6 were selected and these were used 
to check external predictivity whereas models showing pred_
r2 below 0.5 were rejected.
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Table 1. Descriptors utilized in GQSAR model and their description
Sr. no. Class of Descriptor Description
1. Hydrogens Count This descriptor signifies number of hydrogen atoms in a compound.
2. Oxygens Count This descriptor signifies number of oxygen atoms in a compound.
3. 1Path Count This descriptor signifies total number of fragments of first order (bonds) in a compound.
4. Epsilon3 Measure of electronegative atom count including hydrogen atoms with respect to the saturated 
hydrocarbon (reference alkane) created from the molecule/fragment under consideration.
5. Mom Inertia Z This descriptor signifies moment of interia at Z-axix.
6. Radius of Gyration This descriptor signifies size descriptor for the distribution of atomic masses in a molecule.
7. Psi1 A measure of hydrogen–bonding propensity of the molecules and/or polar surface area.
8. slogp This descriptor signifies log of the octanol/water partition coefficient.
9. chiV3Cluster This descriptor signifies valence molecular connectivity index of 3rd order cluster.
10. Epsilon4 Measure of electronegative atom count including hydrogen atoms with respect to the saturated 
hydrocarbon (reference alkane) created from the molecule/fragment under consideration.
11. SsCH3count This descriptor defines the total number of -CH3 group connected with single bond.
12. XlogP This descriptor signifies ratio of solute concentration in octanol & water and generally termed as 
Octanol Water partition Coefficient.
13. HosoyaIndex This descriptor signifies the topological index or Z index of a graph is the total number of matching 
in it plus 1 (“plus 1” accounts for the number of matchings with 0 edges).
14. SsssNcount This descriptor defines the total number of nitrogen connected with three single bonds.
15. MomInertiaY This descriptor signifies moment of interia at Y-axis.
16. SaaCHE-index Electro topological state indices for number of –CH group connected with two aromatic bonds.
17. Rotatable Bond Count Number of rotatable bonds.
18. SaaCHE-index Electro topological state indices for number of –CH group connected with two aromatic bonds.
19. Hydrogens Count This descriptor signifies number of hydrogen atoms in a compound.
20. Oxygens Count This descriptor signifies number of oxygen atoms in a compound.
21. chiV3Cluster This descriptor signifies valence molecular connectivity index of 3rd order cluster.
22. 1PathCount This descriptor signifies total number of fragments of first order (bonds) in a compound.
General structure
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2.4. Validation of the developed GQSAR model
Validation of GQSAR model is most important and critical 
step in development of model. Validation of model is done to 
test the internal stability of model and predictive ability of the 
GQSAR model. Validation is of two types internal (methods 
like the methods of least squares fit (r2), cross-validation (q2), 
adjusted r2 (r2adj), chi-squared test (χ2), Root Mean Squared 
Error (RMSE), bootstrapping and scrambling) and external 
(using a separate test set of molecules). One of the best 
method for validation of a model is an external validation 
method that is evaluation of the QSAR model on a test set of 
molecules (24).
2.4.1 Internal validation
Internal validation of developed model was carried out 
by means of Leave-One-Out (q2, LOO) method (25). To 
calculate q2, every molecule in the training set was removed 
one after the other, and the activity of the removed molecule 
was predicted from the developed model from the remaining 
set of molecules. Equation 1 used to calculate q2 which 
describes the internal stability of the model.
Eq. 1
q2 = 1 – Ʃ (yi -Ўi)2
               Ʃ (yi - ymean)2
Where, yi and ŷi are the actual and predicted activities of the 
ith molecule, individually and y mean is an average activity of 
molecules from training set.
2.4.2 External Validation
For the external validation of the model, activity of individual 
molecule from the test set was predicted using the model 
produced from the molecules in the training set. Equation 2 
used to calculate the pred_r2 value as follows,
Eq. 2
Pred_r2 = 1 – Ʃ (yi -Ўi)2
                   Ʃ (yi - ymean)2
Where, yi and ŷi are the actual and predicted activities of the 
ith molecule, individually and y mean is an average activity of 
molecules from the training set (25, 26).
3. Results and discussion
3.1. GQSAR studies
In the present study we performed a GQSAR on the coumarin 
derivatives as anticoagulant agents reported by Bhatia et 
al.(1). The molecules in the study were randomly divided into 
the training set and test set. 70% of molecules were selected 
for training set and remaining 30% of molecules in test set for 
validation of model. MLR method was used together with SW 
forward-backward variable selection search algorithm with 
cross-correlation limit 0.7 was employed for development of 
the significant GQSAR model. Several GQSAR were models 
developed and best one were selected based on various 
statistical parameters as r2, q2, pred_r2, F-test and standard 
error. The predicted activities of four different GQSAR 
models A, B, C, and D are shown in Table no. 3.
3.2. Interpretation of QSAR Models
The model was selected on basis of r2, q2, pred_r2, F-test and 
standard error to evaluate molecular features that govern the 
anticoagulant potential of the selected derivatives.
GQSAR Model A
The GQSAR models developed based on above statistical 
parameters model A was more significant having r2= 0.72, 
q2 = 0.64 and pred_r2 = 0.54. The dataset used for present 
study and other parameters observed and predicted activity 
of molecules are given in Table 2. The fitness plot for model 
A is shown in figure 1, which shows random distribution of 
predicted versus observed activity of molecules. The model 
A shows descriptors like R1-SaaCHE-index, R2-slogp, R1-
chiV3Cluster, R6-slogp and R1-RotatableBondCount are 
contributed to activity of molecules.
pIC50= 0.3371+0.0294(±0.0003) R1-SaaCHE-index 
+ 0.0802(±0.0093) R2-slogp+ 0.9600(±0.1277) R1-
chiV3Cluster -0.2393(±0.0955) R6-slogp -0.0227(±0.0005) 
R1-RotatableBondCount
Having n= 33, Degree of freedom = 38, in adding to that, the 
randomization test shows confidence of >99.9999% (Alpha 
Rand R^2=0.00001) that indicate the generated model A is 
not random therefore GQSAR model A is chosen as the best 
QSAR model.
R1-SaaCHE-index signifies electro-topological state indices 
for number of –CH group connected with two aromatic 
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Table 2. Table showing dataset used under study
Sr. No. R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
1 =N- H H H H H H H -OH H H
2 =N- H H H H H H H H H Cl-C6H5-
3 =N- H H H H H H H H H -OCH3
#4 =N- H H H H H H H H H H
#5 =N- H H H H H H H H H (CH3)2N-
#6 =N- H H H H H -OCH3 -OCH3 H H -OCH3
7 =N- NO2 H H H H H H -OH H H
8 =N- NO2 H H H H H H H H -Cl
9 =N- NO2 H H H H H H H H -OCH3
#10 =N- NO2 H H H H H H H H H
11 =N- NO2 H H H H H H H H (CH3)2N-
#12 =N- NO2 H H H H -OCH3 -OCH3 H H -OCH3
#13 =N- H H -OH H H H H -OH H H
14 =N- H H -OH H H H H H H -Cl
15 =N- H H -OH H H H H H H -OCH3
16 =N- H H -OH H H H H H H H
17 =N- H H -OH H H H H H H (CH3)2N-
18 =N- H H -OH H H -OCH3 -OCH3 H H -OCH3
19 =N- NO2 H -OH H H H H -OH H H
20 =N- NO2 H -OH H H H H H H -Cl
#21 =N- NO2 H -OH H H H H H H -OCH3
#22 =N- NO2 H -OH H H H H H H H
23 =N- NO2 H -OH H H H H H H (CH3)2N-
#24 =N- NO2 H -OH H H -OCH3 -OCH3 H H -OCH3
#25 =N- H H H H H H H -OH -NH2 H
26 =N- H H H H H H H H -NH2 -Cl
27 =N- H H H H H H H H -NH2 -OCH3
#28 =N- H H H H H H H H -NH2 H
29 =N- H H H H H H H H -NH2 (CH3)2N-
30 =N- H H H H H -OCH3 -OCH3 H -NH2 -OCH3
31 =N- NO2 H H H H H H -OH -NH2 H
32 =N- NO2 H H H H H H H -NH2 -Cl
33 =N- NO2 H H H H H H H -NH2 -OCH3
34 =N- NO2 H H H H H H H -NH2 H
35 =N- NO2 H H H H H H H -NH2 (CH3)2N-
#36 =N- NO2 H H H H -OCH3 -OCH3 H -NH2 -OCH3
37 =N- H NO2 H H H H H -OH -NH2 H
38 =N- H NO2 H H H H H H H -Cl
#39 =N- H NO2 H H H H H H H -OCH3
40 =N- H NO2 H H H H H H H H
41 =N- H NO2 H H H H H H H (CH3)2N-
42 =N- H NO2 H H H -OCH3 -OCH3 H H -OCH3
43 =N- NO2 NO2 H H H H H -OH H H
44 =N- NO2 NO2 H H H H H H H -Cl
#45 =N- NO2 NO2 H H H H H H H -OCH3
46 =N- NO2 NO2 H H H H H H H H
47 =N- NO2 NO2 H H H H H H H (CH3)2N-
#48 =N- NO2 NO2 H H H -OCH3 -OCH3 H H -OCH3
#: indicates molecules in test set
Kumbhar et al.
GQSAR of chromen-2-one derivatives as FXa inhibitorsMarmara Pharm J 21/3: 620-630, 2017 625
bonds which is positively contributing to activity of molecules 
indicates that –CH at R1 contributes positively in activity. R2-
slogp means log of the octanol/water partition coefficient. 
R2-slogp is directly proportional to bioactivity of molecules 
which indicates substitutions of lipophilic groups at R2 
position of pyridine ring will increase in inhibition of FXa. R1-
chiV3Cluster this descriptor signifies that valence molecular 
connectivity index of 3rd order cluster which also contributing 
positively in bioactivity of molecules which indicates increase 
in carbon chain length will potentiate the anticoagulant 
activity, due to occupation of hydrophobic pockets in the 
factor XA. R6-slogp means log of the octanol/water partition 
coefficient. R6-slogp is contributing negatively in bioactivity 
of molecules which indicates substitution of lipophilic group 
at R6 position of substituted benzaldehyde will decrease in 
activity. Lastly descriptor R1-RotatableBondCount means 
Number of rotatable bonds. R1-RotatableBondCount which 
is negatively contributing to activity of molecules that means 
number of rotatable bonds at R1 position should be minimum 
for better activity of molecules.
Activity distribution plot in which green dots represent for 
test set whereas red dots represents training set molecules. 
The y-axis of the plot designate the activity values as in the 
worksheet shown in fig. 2. Plot indicates that the test set 
molecule activities place within the range of training set 
molecules.
Fitness plot for model A is shown in fig. 3. The fitness plot 
gives knowledge about how well best suited model is and how 
much it fit to predict the activity of the external molecules in 
test set. Plot shows that about all molecules are close to the line, 
which gives assurance about predictive capability of model A.
Contribution Plot for model A shows the comparative 
contribution of specific descriptors which plays significant 
role in bio-activity deviation in the developed model shown 
in fig. 4.
Uni Column Statistics:
Uni-Column Statistics: For Training set
Column Name Average Max Min StdDev Sum
pIC50 0.5507 0.8500 0.1600 0.2093 24.2300
Uni-Column Statistics: For Test set
Column Name Average Max Min StdDev Sum
pIC50 0.5715 0.7800 0.1800 0.1954 8.4300
Uni-column statistics of model A shows that average of test 
set is somewhat greater than average of training set which 
indicates dataset used for current study have comparatively 
more active molecules than inactive molecules. The value 
of max of test set less than training set and value of min of 
test set greater than training set which indicate that test set is 
derived in between min-max range of training set molecules. 
Standard deviation of training set is higher than test set this 
signifies that training set molecules has extensively scattered 
activity than test set molecules.
Figure 2. Activity distribution plot of Model A
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GQSAR Model B
The obtained GQSAR model B was also statistically more 
significant with value of r2 = 0.70, q2 = 0.61 and pred_r2 = 
0.55. The equation for model B as follows,
pIC50= 0.3384+ 0.1574(±0.0088) R2-HydrogensCount 
-0.0843(±0.0129) R1-OxygensCount+ 0.5842(±0.1449) R1-
chiV3Cluster -0.2565(±0.0996) R6-slogp
With, n= 33, Degree of freedom= 39, Alpha Rand 
R^2=0.00000 which indicate developed model was good in 
prediction of activity.
The developed model B shows that descriptor R2-
HydrogensCount means number of hydrogen atoms in a 
compound at R2 site plays vital role and which is directly 
proportional to regulate activity of molecules. That signifies 
increase in hydrogen atom count at R2 position will increase 
Figure 3. Fitness plot of model A comparison of observed versus predicted activity
Figure 4. Contribution Plot of developed model A
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Table 3. Showing statistical parameters of dataset (Observed and Predicted activity)
Compound code Observed activity 
pIC50
Predicted activity pIC50
Model A Model B Model C Model D
1 0.85 0.85 0.86 0.89 0.85
2 0.78 0.78 0.75 0.83 0.82
3 0.79 0.60 0.60 0.63 0.69
#4 0.65 0.65 0.64 0.68 0.66
#5 0.66 0.81 0.82 0.92 0.83
#6 0.59 0.49 0.49 0.52 0.50
7 0.38 0.44 0.43 0.43 0.40
8 0.55 0.63 0.60 0.64 0.65
9 0.31 0.45 0.44 0.44 0.52
#10 0.44 0.49 0.49 0.49 0.49
11 0.78 0.66 0.66 0.73 0.67
#12 0.52 0.34 0.33 0.33 0.34
#13 0.55 0.59 0.59 0.62 0.57
14 0.78 0.78 0.75 0.83 0.82
15 0.81 0.60 0.60 0.63 0.69
16 0.68 0.64 0.64 0.68 0.66
17 0.75 0.81 0.82 0.92 0.83
18 0.35 0.49 0.49 0.52 0.50
19 0.45 0.44 0.43 0.43 0.40
20 0.8 0.63 0.60 0.64 0.65
#21 0.21 0.45 0.44 0.44 0.52
#22 0.32 0.49 0.49 0.49 0.49
23 0.75 0.66 0.66 0.73 0.67
#24 0.25 0.34 0.33 0.33 0.34
#25 0.61 0.59 0.59 0.62 0.57
26 0.77 0.78 0.75 0.83 0.82
27 0.65 0.60 0.60 0.63 0.68
#28 0.79 0.65 0.64 0.68 0.66
29 0.78 0.81 0.82 0.92 0.83
30 0.49 0.49 0.49 0.52 0.50
31 0.49 0.44 0.43 0.43 0.40
32 0.72 0.63 0.60 0.64 0.65
33 0.36 0.50 0.44 0.44 0.52
34 0.39 0.49 0.49 0.49 0.49
35 0.61 0.66 0.66 0.73 0.67
#36 0.3 0.34 0.33 0.33 0.34
37 0.57 0.59 0.59 0.52 0.46
38 0.68 0.78 0.75 0.73 0.71
#39 0.46 0.60 0.60 0.53 0.57
40 0.69 0.65 0.64 0.57 0.55
41 0.83 0.81 0.82 0.82 0.72
42 0.4 0.49 0.49 0.41 0.39
43 0.35 0.44 0.43 0.33 0.29
44 0.65 0.63 0.60 0.54 0.54
#45 0.18 0.50 0.44 0.34 0.41
46 0.21 0.49 0.49 0.38 0.38
47 0.7 0.66 0.66 0.63 0.56
#48 0.29 0.34 0.33 0.22 0.23
#: indicates molecules in test set
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bioactivity of molecules. Another important factor which 
regulates the activity of molecule is number of oxygen 
atoms in a compound at R1 site (R1-OxygensCount) which 
is negatively contributing to activity of molecules. At R1 
site of molecule R1-chiV3Cluster which signifies valence 
molecular connectivity index of 3rd order cluster which is 
directly proportional to activity of molecules. Last but not 
least another important factors that governing deviation in 
the bioactivity of molecules is the log of partition coefficient 
at R6 substitution site (R6-slogp) which is negatively 
contributed in bioactivity of molecules. This signifies that 
substitution of lipophilic group at R6 position of substituted 
benzaldehyde will contribute to diminution in activity.
GQSAR Model C
The generated model C was also having significant statistical 
values, r2 = 0.68, q2 = 0.43 and pred_r2 = 0.57. The equation 
generated for model C as follows,
pIC50= 0.3443+ 0.1897(±0.0117) R2-HydrogensCount 
-0.1003(±0.0146) R1-OxygensCount+ 0.8291(±0.1753) 
R1-chiV3Cluster -0.2003(±0.0794) R3-Epsilon4 
-0.2565(±0.1168) R6-slogp
With, n= 33, Degree of freedom= 38, Alpha Rand 
R^2=0.00002 which designate that developed model was 
good in prediction of activity.
The developed model C shows that the descriptor R2-
HydrogensCount signifies that number of hydrogen 
atoms in a compound at R2 site plays key role and which 
is positively contributed to regulating the activity of 
molecules. This means increase in hydrogen atom count 
at R2 position will increase bioactivity of molecules. At R1 
position of molecule descriptor R1-OxygensCount which 
is inversely proportional to activity of molecules. R1-
chiV3Cluster that signifies valence molecular connectivity 
index of 3rd order cluster which is positively contributed 
to bioactivity of molecules. Another important descriptor 
at R3 position which is also inversely proportional in 
determining bioactivity of molecules is R3-Epsilon4 
which signifies Measure of electronegative atom count 
including hydrogen atoms with respect to the saturated 
hydrocarbon (reference alkane) created from the molecule/
fragment under consideration. That means substitution 
of electronegative atom at R3 position will diminish the 
activity of molecules. R6-slogp signifies log of the octanol/
water partition coefficient. R6-slogp is contributing 
negatively in bioactivity of molecules which means that the 
substitution of lipophilic group at R6 position of substituted 
benzaldehyde will diminish the activity of molecules.
GQSAR Model D
The GQSAR model D shows the significant statistical values 
as, r2 = 0.68, q2 = 0.59 and pred_r2 = 0.51. The equation 
generated for model D as follows,
pIC50= 0.3615+ 0.1634(±0.0173) R2-HydrogensCount 
-0.0905(±0.0201) R1-OxygensCount -0.0370(±0.0146) R3-
1PathCount + 0.3060(±0.0943) R11-Psi1 -0.2588(±0.1162) 
R6-slogp
With, n= 33, Degree of freedom= 38, Alpha Rand 
R^2=0.00000 which means developed model was good in 
prediction of activity.
In the developed model D the descriptor R2-HydrogensCount 
signifies that number of hydrogen atoms in a compound at 
position R2 plays an important role in regulating activity and 
which is positively contributing to bioactivity of molecules. 
That indicates that increase in hydrogen atom count at 
R2 position will increase bioactivity of molecules. R1-
OxygensCount which is negatively contributing to activity 
of molecules at R1 position of molecule. Another important 
descriptor 1PathCount at R3 position also govern the bio-
activity of molecule, this descriptor signifies total number 
of fragments of first order (bonds) in a compound. Which 
is inversely proportional to activity of molecules means 
increase in fragments of bonds will reduce the bioactivity 
of molecules. At R11 site the descriptor R11-Psi1 which is 
positively governing the activity of molecules. Descriptor 
Psi1 measures the hydrogen–bonding tendency of the 
molecules and/or polar surface area. That signifies that 
polar surface area and hydrogen–bonding tendency of 
the molecules are directly proportional to bioactivity of 
molecules. Finally, the presence of descriptor R6-slogp which 
is inversely proportional to bioactivity of molecules shows 
the role of substitution of lipophilic group at R6 position in 
determination of activity of molecules.
4. Conclusion
Present communication is an attempt to identify structural 
features of chromen-2-one derivatives for this we performed 
fragment based GQSAR. In the present study GQSAR models 
were developed on the series of 48 chromen-2-one derivatives 
having potential FXa inhibition activity. The dataset of 48 
molecules were randomly divided in such way that 70% 
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molecules in training set and remaining 30% molecules were 
in test set, and GQSAR models were developed with Multiple 
linear regression (MLR) method coupled with stepwise 
(SW) forward-backward variable selection search algorithm 
was employed. Four different models A, B, C and D were 
developed. Based on statistical parameters r2, q2, F-test and 
standard error models were validated. Model A was found to 
be good over the other developed models because it fulfils all 
the parameters and having r2 value significantly more than 
other models. The developed model A shows descriptors like 
R1-SaaCHE-index, R2-slogp, R1-chiV3Cluster, R6-slogp 
and R1-RotatableBondCount are contributed to activity of 
molecules. Out of that R6-slogp and R1-RotatableBondCount 
are negatively contributed in bioactivity of molecules and 
others are positively contributed to enhance activity. R2-
slogp is positively contributed to bioactivity of molecules 
which indicates substitutions of lipophilic groups at R2 
position of pyridine ring will enhances inhibition of FXa. 
The four developed GQSAR models A, B, C and D are having 
one common descriptor R6-slogp and which is negatively 
contributing to activity. Presence of lipophilic group at R6 
position of molecule will lessen the activity of molecule. As 
GQSAR helps in providing site specific clues along with 
specific descriptor this will helpful in better understanding of 
drug design. From the designed models it can be concluded 
that at R6 position if we substitute the lipophilic group 
the activity of designed molecules will be diminishes. The 
GQSAR model development is a valuable tool to researchers 
and medicinal chemist to design and develop potent lead 
molecule with lesser side effects. Thus, the data obtained 
from this GQSAR model will helpful for the design and 
development of novel lead molecules to yield potent FXa 
inhibitors.
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Fxa inhibitörü etkili sübstitüe kromen-2-on bileşiklerinin 
fragment temelli kantitatif regresyon özelliklerinin 
incelenmesi
ÖZ
Faktör Xa (FXa), tripsin-benzeri bir serin proteaz olup 
antikoagülan etkili bileşiklerin tasarlanmasında temel alınan 
önemli bir hedeftir. Literatürde, Faktör Xa inhibitörü olduğu 
bildirilen birçok bileşiğin farmakokinetik açıdan sorunlu 
olduğu bildirilmektedir. Bu çalışmada, FXa’yı önemli ölçüde 
inhibe eden 48 kromen-2-on türevinin grup temelli kantitatif 
yapı etki ilişkisi (GQSAR) üzerinde çalışılmış ve elde edilen 
bulgular doğrulanmıştır. Bütün bileşikler onbir fonksiyonel 
fragmente (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 ve R11) 
ayrılarak incelenmiştir. Geliştirilen tüm GQSAR modelleri çoklu 
lineer regresyon analizi (MLR) kullanılarak oluşturulmuştur. 
Geliştirilen GQSAR modellerinden r2 değerleri 0.6’nın üzerinde 
olanlar istatistiksel yöntemler doğrultusunda seçilmiş ve dış 
tahmine dayalı analiz yönteminin sağlamasını yapmak amacıyla 
kullanılmış, oluşturulan modelin anlamlılığı F değeri dikkate 
alınarak tanımlanmıştır. Geliştirilen GQSAR modelleri; lipofilik 
grupların fragment R6 üzerindeki varlığının biyoaktiviteyi 
azalttığını, fragment R2 üzerinde bulunmaları durumunda ise 
biyoaktivitenin arttığını göstermiştir. Buna ek olarak, fragment 
R1’de minimum sayıda dönebilen bağ olması durumunun FXa 
inhibisyonunu arttırdığı tespit edilmiştir. GQSAR modellerinin 
incelenmesi ile elde edilen sonuçların yeni FXa inhibitörlerinin 
tasarımı ve geliştirilmesi için yararlı olduğu düşünülmektedir.
Anahtar kelimeler: FXa, Vlife MDS, Antikoagülan, Kantitatif 
Yapı Etki İlişkisi, GQSAR, Slogp
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